Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CFX Stock Forecast 2026-2027
$26.27
Current Price
$1.41B
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CFX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CFX Price Momentum
+3.7%
1 Week Change
+20.2%
1 Month Change
-19.5%
1 Year Change
-1.4%
Year-to-Date Change
-30.6%
From 52W High of $37.85
+25.1%
From 52W Low of $21.00
📊 TOP ANALYST CALLS
Did CFX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Colfax is one of their latest high-conviction picks.
Latest CFX Stock Price Targets & Analyst Predictions
CFX has shown a year-to-date change of -1.4% and a 1-year change of -19.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for CFX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CFX Analyst Ratings
0
Buy
0
Hold
0
Sell
CFX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $26.27
Latest CFX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CFX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Enovis Corporation (CFX) Competitors
The following stocks are similar to Colfax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enovis Corporation (CFX) Financial Data
Enovis Corporation has a market capitalization of $1.41B with a P/E ratio of 28.6x. The company generates $3.85B in trailing twelve-month revenue with a 41.9% profit margin.
Revenue growth is +0.0% quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +97.9%.
Valuation Metrics
Market Cap
$1.41B
Enterprise Value
$2.97B
P/E Ratio
28.6x
PEG Ratio
-0.9x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
+0.0%
Gross Margin
+42.0%
Operating Margin
N/A
Net Margin
+41.9%
EPS Growth
+16.4%
Financial Health
Cash/Price Ratio
N/A
Current Ratio
2.2x
Debt/Equity
50.4x
ROE
+97.9%
ROA
+2.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enovis Corporation (CFX) Business Model
About Enovis Corporation
What They Do
Develops innovative orthopedic care solutions.
Business Model
Enovis Corporation generates revenue through two primary segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment focuses on bracing and supports that aid injury prevention and patient recovery, while the Reconstructive segment offers joint replacement products and surgical solutions aimed at restoring mobility.
Additional Information
The company, formerly part of Colfax Corporation, has transitioned into a dedicated medical technology firm through strategic acquisitions, including DJO, and the divestiture of its fabrication technology segment. Enovis is committed to improving clinical outcomes and enhancing healthcare workflows, serving a global customer base including hospitals and clinics.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,367
CEO
Mr. Damien McDonald
Country
United States
IPO Year
2008
Website
www.enovis.comEnovis Corporation (CFX) Latest News & Analysis
Latest News
Quick Summary
Canfor Pulp Products Inc. held a shareholder and analyst call, providing updates on company performance and future outlook. Further details can be found in the transcript.
Why It Matters
The transcript provides insights into Canfor’s financial health, strategic direction, and market outlook, influencing investor sentiment and potential stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Enovis Corporation (NYSE: ENOV) completed its separation from ESAB Corporation (NYSE: ESAB), creating an independent company. Enovis also executed a one-for-three reverse stock split.
Why It Matters
The separation of Enovis from ESAB creates two distinct investment opportunities, affecting stock valuations and investor strategies. The reverse split may also impact liquidity and share price perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ESAB Corp. will join the S&P MidCap 400 on April 5, 2022. PROG Holdings will replace Fiesta Restaurant Group in the S&P SmallCap 600 on April 6, 2022.
Why It Matters
ESAB Corp.'s addition to the S&P MidCap 400 can boost its visibility and demand from institutional investors, potentially affecting its stock price positively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Colfax Corporation will be renamed Enovis following its spin-off of the fabrication technology business, which will operate as ESAB Corporation. The spin-off is expected to complete on April 4, 2022.
Why It Matters
The spin-off may enhance shareholder value by allowing Enovis to focus on its core operations while ESAB can specialize in fabrication technology, potentially improving both companies' performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Colfax (CFX) reported earnings 30 days ago; investors should monitor upcoming developments and performance indicators for future stock movements.
Why It Matters
Earnings reports can influence stock price and investor sentiment. Upcoming performance expectations may drive trading activity and valuation for Colfax.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
KeyBanc analyst Jeffrey Hammond lowered Colfax Corp's price target to $52 from $60, citing lower peer multiples, while maintaining an Overweight rating. The new target suggests a 41% upside.
Why It Matters
Colfax Corp's lowered price target indicates reduced growth expectations, but the maintained Overweight rating suggests potential for upside, making it a stock to watch.
Source: Benzinga
Market Sentiment:
Negative
Frequently Asked Questions About CFX Stock
What is Enovis Corporation's (CFX) stock forecast for 2026?
Analyst forecasts for Enovis Corporation (CFX) are not currently available. The stock is trading at $26.27.
Is CFX stock a good investment in 2026?
Analyst ratings for CFX are not currently available. The stock is currently trading at $26.27. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CFX stock?
Price predictions from Wall Street analysts for CFX are not currently available. The stock is trading at $26.27.
What is Enovis Corporation's business model?
Enovis Corporation generates revenue through two primary segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment focuses on bracing and supports that aid injury prevention and patient recovery, while the Reconstructive segment offers joint replacement products and surgical solutions aimed at restoring mobility.
What is the highest forecasted price for CFX Enovis Corporation?
Price targets from Wall Street analysts for CFX are not currently available. The stock is trading at $26.27.
What is the lowest forecasted price for CFX Enovis Corporation?
Price targets from Wall Street analysts for CFX are not currently available. The stock is trading at $26.27.
What is the overall CFX consensus from analysts for Enovis Corporation?
Analyst ratings for CFX are not currently available. The stock is trading at $26.27.
How accurate are CFX stock price projections?
Stock price projections, including those for Enovis Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 6:20 AM UTC